Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Operating Income (2022 - 2024)

Summit Therapeutics' Operating Income history spans 3 years, with the latest figure at -$65.6 million for Q4 2024.

  • For Q4 2024, Operating Income fell 81.2% year-over-year to -$65.6 million; the TTM value through Dec 2024 reached -$226.0 million, up 62.93%, while the annual FY2024 figure was -$226.0 million, 62.93% up from the prior year.
  • Operating Income reached -$65.6 million in Q4 2024 per SMMT's latest filing, down from -$58.4 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$15.8 million in Q2 2023 to a low of -$537.2 million in Q1 2023.
  • Average Operating Income over 3 years is -$87.3 million, with a median of -$39.3 million recorded in 2023.
  • The largest YoY upside for Operating Income was 92.11% in 2024 against a maximum downside of 277.47% in 2024.
  • A 3-year view of Operating Income shows it stood at -$20.3 million in 2022, then tumbled by 78.38% to -$36.2 million in 2023, then plummeted by 81.2% to -$65.6 million in 2024.
  • Per Business Quant, the three most recent readings for SMMT's Operating Income are -$65.6 million (Q4 2024), -$58.4 million (Q3 2024), and -$59.6 million (Q2 2024).